Tag:
PN 400
Latest Headlines
Latest Headlines
Pozen's shares soar as FDA approves study results
Chapel Hill, NC-based Pozen saw its stock soar Thursday on the news that the FDA accepted its primary endpoint for two late-stage clinical trials PN 400, its arthritis drug. PN 400, which is being
Pozen touts positive data on new arthritis therapy
Pozen has taken another step toward the regulatory approval of a new arthritis treatment. The Chapel Hill, NC biotech says that PN 400--which is partnered with AstraZeneca--produced new data
AstraZeneca, Pozen start Phase III combo drug trial
AstraZeneca and Pozen are starting Phase III trial of PN400, an experimental drug for arthritis pain that combines AstraZeneca's heartburn drug Nexium with the anti-inflammatory drug naproxen. In
